Financial Data and Key Metrics Changes - Year-over-year revenue increased by 14.7%, driven entirely by organic growth, keeping within the anticipated range for organic growth during the year [23] - Gross margin for the quarter was 58.3%, down from 59.8% in 2024 and 56.3% in 2025, reflecting a decline consistent with previous quarters [23][24] - Adjusted EBITDA grew 12% year-over-year to $14.3 million, with an adjusted EBITDA margin of 22.7% [24][30] Business Line Data and Key Metrics Changes - Ventilation business accounted for 54% of revenues, with vent revenue up 5% sequentially and 11% year-over-year [11][23] - Sleep therapy patients increased by 15% sequentially and 51% year-over-year, with new patient sales up 72% year-over-year [12][23] - Resupply program patients were up 10% sequentially and 25% year-over-year, indicating strong growth in this segment [13] - Staffing business experienced a sequential slowdown due to softened labor demand, although it was up year-over-year [14][20] Market Data and Key Metrics Changes - The sleep business now represents 19% of total revenues, reflecting its rapid growth and importance to the overall revenue mix [23][45] - The staffing business, which accounts for approximately 10% of total revenue, is primarily driven by behavioral and social service needs [20] Company Strategy and Development Direction - The company is focused on expanding its addressable at-home market, with the acquisition of Lehan Medical Equipment marking a strategic step into maternal health [8][10] - The company aims to diversify its patient base and leverage existing infrastructure to reach new patient populations [8][10] - The management emphasizes disciplined execution of long-term strategies, resulting in tangible growth across core and complementary services [6][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the evolving regulatory landscape, particularly with the new NCD final rule, which is expected to reduce operational burdens [15][18] - The company anticipates continued organic growth and has raised its full-year guidance for net revenue and adjusted EBITDA, reflecting optimism for the second half of the year [30][32] - Management noted that the industry is well-positioned to educate regulators and present solutions, enhancing the company's competitive stance [18][19] Other Important Information - The company has a strong balance sheet with $55 million available on credit facilities and $20 million in cash, enabling share repurchase programs and acquisitions [28][29] - The company completed a ventilator exchange program, which is expected to normalize CapEx going forward and improve adjusted free cash flow [26][30] Q&A Session Summary Question: Can you elaborate on the benefits of the BENT program upgrade and exchanges? - The financial benefits include cash back for the vents, generally higher than net book value, and the clinical value lies in acquiring newer, technologically advanced assets [35][36] Question: What is the administration's view on DME in general? - The administration is looking to cut costs across government sectors, and competitive bidding pressure is anticipated [39][40] Question: Were there any unusual factors contributing to the growth in sleep therapy patient count? - Growth is attributed to an expanded sales force and increased operational efficiency, with no significant negative impact from GLP-1s [44][45] Question: What drove the decline in service revenue in the staffing business in Q2? - The decline is linked to behavioral health and social service needs, with expectations for appropriations to improve in the back half of the year [48][49]

Q2 2025 Key Financial Highlights - Revenue grew by 15% year-over-year in Q2[7] - Net income increased by 120% year-over-year for Q2[7] - Adjusted EBITDA increased by 12% year-over-year for Q2, reaching 22.7% of revenue, aligning with the full-year outlook[7] - The company repurchased 270,061 common shares for $1.8 million, at an average price of $6.79 per share[7] Operational Performance - Vent patient growth was robust, with an 11% year-over-year increase in Q2 and a 3% sequential increase from Q1[7] - Sleep therapy patients increased significantly, up 51% year-over-year and 15% sequentially in Q2; new sleep patient starts were up 72% year-over-year, and sleep resupply patient count was up 25% year-over-year and 10% sequentially[7] Financial Position and Strategy - The company completed the strategic acquisition of Lehan's Medical Equipment on July 1, 2025, expected to contribute starting in Q3[6] - As of June 30, 2025, the company had $55 million in unfunded commitments available under its existing credit facilities[19] - The company maintains a healthy balance sheet with no net debt as of June 30, 2025[19] 2025 Guidance - Net revenue is projected to be between $271 million and $277 million, an increase from the previous guidance of $256 million to $265 million[22] - Adjusted EBITDA is expected to be between $59 million and $62 million, representing 22% of net revenue, an increase from the previous guidance of $55 million to $58 million[22]

[Report Information](index=1&type=section&id=Report%20Information) Viemed Healthcare, Inc. filed its Q2 2025 Form 10-Q, identifying as an accelerated filer with 38.8 million common shares outstanding - Viemed Healthcare, Inc. submitted its Form 10-Q quarterly report for the period ended June 30, 2025[1](index=1&type=chunk) - The company's stock ticker is VMD, listed on The Nasdaq Stock Market LLC[3](index=3&type=chunk) - The company is designated as an **Accelerated Filer**[4](index=4&type=chunk) - As of July 31, 2025, the company had **38,785,759 common shares outstanding**[4](index=4&type=chunk) [PART I - FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) This section presents the company's unaudited condensed consolidated financial statements and notes for the periods ended June 30, 2025 and 2024 [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section includes the company's unaudited condensed consolidated financial statements, comprising balance sheets, income statements, statements of changes in shareholders' equity, and cash flow statements, along with notes for the periods ended June 30, 2025, and 2024 [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This statement details the company's financial position, including assets, liabilities, and shareholders' equity, as of specific reporting dates Condensed Consolidated Balance Sheets Key Data (in thousands of dollars) | Metric | June 30, 2025 (Unaudited) | December 31, 2024 (Audited) | Change ($) | Change (%) | | :--------------------------------- | :-------------------------- | :-------------------------- | :--------- | :--------- | | **Assets** | | | | | | Total current assets | $55,291 | $52,880 | $2,411 | 4.56% | | Total long-term assets | $129,312 | $124,189 | $5,123 | 4.12% | | **Total Assets** | **$184,603** | **$177,069** | **$7,534** | **4.25%** | | **Liabilities** | | | | | | Total

VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS Lafayette, Louisiana (August 6, 2025) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced today that it has reported its financial results for the three and six months ended June 30, 2025. Operational highlights (all dollar amounts are USD; comparisons are to the period ended June 30, 2024 unless otherwis ...

Core Viewpoint - Viemed Healthcare, Inc. has announced a share repurchase program, allowing the company to buy back up to 1,976,441 common shares, which is approximately 5% of the total shares outstanding as of March 31, 2025, to enhance shareholder value [1][2]. Group 1: Share Repurchase Program - The share repurchase program is effective through June 2026 and allows for purchases through open market transactions, block purchases, or other methods compliant with securities laws [1][3]. - Daily purchases will be limited to 25% of the average daily volume for the four weeks preceding the purchase date, with the price paid being the market price at the time of purchase plus applicable brokerage fees [3][4]. - The company has previously repurchased approximately 2.6 million shares since its public listing, demonstrating a commitment to disciplined capital allocation [4]. Group 2: Financial Position and Strategy - Viemed's CEO highlighted strong first quarter 2025 results and increased guidance, indicating robust underlying business fundamentals [4]. - The company has no net debt and full access to a $55 million credit facility, providing ample liquidity for both the share repurchase program and funding growth initiatives [4]. - The company is also in the process of acquiring Lehan's Medical, expected to close in the third quarter of 2025, further supporting its growth strategy [4]. Group 3: Company Overview - Viemed Healthcare is a provider of in-home clinical care for post-acute respiratory healthcare, offering services such as non-invasive ventilators, sleep therapy, and staffing [5]. - The company focuses on delivering efficient in-home treatment through clinical practitioners who provide therapy, education, and counseling using advanced technology [5].

Company Overview - Viemed Healthcare, Inc. is a national leader in respiratory care and technology-enabled home medical equipment services in the United States [2] - The company specializes in post-acute respiratory healthcare equipment and services, including non-invasive ventilators, sleep therapy, and staffing [2] - Viemed focuses on providing efficient and effective in-home treatment through clinical practitioners who deliver therapy, education, and counseling to patients [2] Event Announcement - Viemed will present at the East Coast IDEAS Investor Conference on June 11, 2025, at The Westin Times Square in New York, NY [1] - The presentation is scheduled to begin at 11:30 am ET and will be webcasted [1] - Access to the webcast is available through the conference host's website and Viemed's investor relations section [1] IDEAS Investor Conferences - The IDEAS Conferences aim to provide independent venues for quality companies to present their investment merits to investment professionals [3] - These conferences are sponsored by investors for the benefit of regional investment communities, with sponsors managing over $200 billion in assets [3] - The conferences are produced annually by Three Part Advisors, LLC [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-38973 Viemed Healthcare, Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other ...

[First Quarter 2025 Earnings Announcement](index=1&type=section&id=First%20Quarter%202025%20Earnings%20Announcement) Viemed Healthcare, Inc. announced its financial results for Q1 2025 and updated full-year 2025 guidance [Announcement Details](index=1&type=section&id=Announcement%20Details) Viemed Healthcare, Inc. announced its financial results for the first quarter ended March 31, 2025, and provided updated guidance for the full year ending December 31, 2025 - Viemed Healthcare, Inc. (NASDAQ:VMD) reported Q1 2025 financial results and updated full-year 2025 guidance[1](index=1&type=chunk) [Q1 2025 Performance & Strategic Updates](index=1&type=section&id=Q1%202025%20Performance%20%26%20Strategic%20Updates) Viemed Healthcare achieved substantial financial and operational growth in Q1 2025, updated full-year guidance, and announced a strategic acquisition [Q1 2025 Financial Highlights](index=1&type=section&id=Q1%202025%20Financial%20Highlights) Viemed Healthcare achieved substantial financial growth in Q1 2025, with net revenues increasing by 17% and net income attributable to Viemed rising by 64% year-over-year. Adjusted EBITDA also saw a 26% increase Financial Highlights | Metric | Q1 2025 (USD) | Q1 2024 (USD) | Change (YoY) | | :----- | :------------ | :------------ | :----------- | | Net Revenues | $59.1 million | $50.6 million | +17% | | Net Income Attributable to Viemed | $2.6 million | $1.6 million | +64% | | Diluted EPS | $0.06 | $0.04 | +50% | | Adjusted EBITDA | $12.8 million | $10.1 million | +26% | [Operational Highlights (Patient Counts)](index=1&type=section&id=Operational%20Highlights%20%28Patient%20Counts%29) The company demonstrated robust operational growth in Q1 2025, significantly increasing its ventilator and PAP therapy patient counts year-over-year, while sleep resupply patients also grew Patient Counts | Patient Type | March 31, 2025 | March 31, 2024 | Change (YoY) | December 31, 2024 | Change (QoQ) | | :----------- | :------------- | :------------- | :----------- | :---------------- | :----------- | | Ventilator Patients | 11,809 | 10,450 | +13% | 11,795 | +0.1% | | PAP Therapy Patients | 22,899 | 15,726 | +46% | 21,338 | +7% | | Sleep Resupply Patients | 22,941 | 18,904 | +21% | 24,478 | -6% | - The company maintains a strong cash balance of **$10.2 million** and an overall working capital balance of **$13.6 million** as of March 31, 2025, with **$55 million** available under existing credit facilities[6](index=6&type=chunk) [Updated Full Year 2025 Guidance](index=1&type=section&id=Updated%20Full%20Year%202025%20Guidance) Viemed Healthcare tightened its full-year 2025 guidance by raising the lower end of its revenue and Adjusted EBITDA ranges, reflecting confidence in continued performance Full Year 2025 Guidance | Metric | Previous FY2025 Guidance (USD) | Updated FY2025 Guidance (USD) | | :----- | :----------------------------- | :---------------------------- | | Net Revenue | $254 million to $265 million | $256 million to $265 million | | Adjusted EBITDA | $54 million to $58 million | $55 million to $58 million | [Agreement to Acquire Lehan's Medical Equipment](index=1&type=section&id=Agreement%20to%20Acquire%20Lehan%27s%20Medical%20Equipment) Viemed Healthcare announced an agreement to acquire Lehan's Medical Equipment for approximately $26 million, expanding its respiratory care and women's health services. The acquisition's impact is not yet included in the current 2025 guidance - Viemed agreed to acquire Lehan's Medical Equipment, a healthcare company specializing in respiratory care and women's health, for approximately **$26 million**, subject to adjustments and contingent payments[4](index=4&type=chunk)[6](index=6&type=chunk) - In 2024, Lehan's generated approximately **$25.7 million** in net revenues and **$7.4 million** in Adjusted EBITDA[6](index=6&type=chunk) - The acquisition is expected to close in the third quarter of 2025, and its anticipated impact is not included in the current full-year 2025 guidance[6](index=6&type=chunk) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) CEO Casey Hoyt highlighted marked improvements across all businesses in Q1, attributing success to 2024 sales organization restructuring, accelerated hiring, and technology investments. He emphasized the strong balance sheet supporting ventilator fleet improvements and inorganic growth opportunities like the Lehan's acquisition, while noting no adverse impact from the macro environment - Q1 2025 performance is directly attributable to the structure put in place in 2024 to improve the sales organization, accelerate new rep hiring, and leverage technology investments for greater efficiencies[5](index=5&type=chunk)[7](index=7&type=chunk) - A strong balance sheet facilitates the significant improvement and extension of the ventilator fleet, primarily funded by an existing buyback program from a large supplier[8](index=8&type=chunk) - Strong capital position and cash flow enable inorganic growth, such as the acquisition of Lehan's Medical Equipment, complementing growth in complex respiratory, sleep, and staffing businesses[8](index=8&type=chunk) - The company has seen no impact from tariffs or a pullback from providers and payers, with its clinical approach offering greater patient satisfaction, fewer hospital readmissions, and lower total cost of care[9](index=9&type=chunk) [Company Overview & Investor Information](index=3&type=section&id=Company%20Overview%20%26%20Investor%20Information) This section provides details on the upcoming conference call, an overview of Viemed Healthcare's business, and investor relations contact information [Conference Call Details](index=3&type=section&id=Conference%20Call%20Details) Viemed Healthcare will host a conference call on May 8, 2025, to discuss Q1 results and 2025 guidance, with dial-in and webcast options available - A conference call to discuss first quarter results and 2025 guidance will be held on Thursday, May 8, 2025, at 11:00 a.m. EDT[10](index=10&type=chunk) - Interested parties may participate by dialing 866-682-6100 (US Toll-Free) or +1-862-298-0702 (International), or via a live audio webcast[11](index=11&type=chunk) [ABOUT VIEMED HEALTHCARE, INC.](index=3&type=section&id=ABOUT%20VIEMED%20HEALTHCARE%2C%20INC.) Viemed Healthcare, Inc. is a U.S. in-home clinical care provider specializing in post-acute respiratory healthcare equipment and services, including non-invasive ventilators, sleep therapy, and staffing, focusing on high-touch and high-tech in-home treatment - Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States[12](index=12&type=chunk) - Services include non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products, with a focus on efficient and effective in-home treatment using clinical practitioners and technology[12](index=12&type=chunk) [Investor Relations Contact](index=3&type=section&id=Investor%20Relations%20Contact) Contact information for investor relations is provided for inquiries - Investor relations can be reached via email at ir@viemed.com or by contacting Tripp Sullivan (SCR Partners, LLC) or Trae Fitzgerald (Chief Financial Officer, Viemed Healthcare, Inc.)[13](index=13&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents the condensed consolidated balance sheets, statements of income, and statements of cash flows for Viemed Healthcare [Condensed Consolidated Balance Sheets](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of March 31, 2025, Viemed Healthcare reported total assets of $178.1 million, a slight increase from December 31, 2024, with a decrease in cash and cash equivalents but an increase in accounts receivable. Total liabilities decreased, while shareholders' equity increased Condensed Consolidated Balance Sheets | Metric (in thousands USD) | March 31, 2025 | December 31, 2024 | Change | | :------------------------ | :------------- | :---------------- | :----- | | Cash and cash equivalents | $10,160 | $17,540 | $(7,380) | | Accounts receivable, net | $26,789 | $24,911 | $1,878 | | Total current assets | $49,120 | $52,880 | $(3,760) | | Total assets | $178,079 | $177,069 | $1,010 | | Total current liabilities | $35,487 | $37,326 | $(1,839) | | Total liabilities | $41,330 | $43,768 | $(2,438) | | Total shareholders' equity | $136,749 | $133,301 | $3,448 | [Condensed Consolidated Statements of Income](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20INCOME) For the three months ended March 31, 2025, Viemed Healthcare reported a significant increase in revenue and net income compared to the prior year, driven by higher gross profit and improved income from operations Condensed Consolidated Statements of Income | Metric (in thousands USD) | Q1 2025 | Q1 2024 | Change | % Change | | :------------------------ | :------ | :------ | :----- | :------- | | Revenue | $59,129 | $50,593 | $8,536 | 16.9% | | Cost of revenue | $25,850 | $20,791 | $5,059 | 24.3% | | Gross profit | $33,279 | $29,802 | $3,477 | 11.7% | | Income from operations | $3,841 | $2,204 | $1,637 | 74.3% | | Net income attributable to Viemed Healthcare, Inc. | $2,625 | $1,603 | $1,022 | 63.8% | | Diluted EPS | $0.06 | $0.04 | $0.02 | 50.0% | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) In Q1 2025, Viemed Healthcare generated $2.85 million in cash from operating activities, an increase from the prior year. However, significant investments in property and equipment led to a net decrease in cash and cash equivalents for the period Condensed Consolidated Statements of Cash Flows | Cash Flow Activity (in thousands USD) | Q1 2025 | Q1 2024 | Change | | :------------------------------------ | :------ | :------ | :----- | | Net cash provided by operating activities | $2,854 | $1,175 | $1,679 | | Net cash used in investing activities | $(8,530) | $(5,365) | $(3,165) | | Net cash used in financing activities | $(1,704) | $(1,340) | $(364) | | Net decrease in cash and cash equivalents | $(7,380) | $(5,530) | $(1,850) | | Cash and cash equivalents at end of period | $10,160 | $7,309 | $2,851 | [Non-GAAP Measures & Supplemental Data](index=8&type=section&id=Non-GAAP%20Measures%20%26%20Supplemental%20Data) This section provides details on non-GAAP financial measures, including Adjusted EBITDA reconciliation, and key financial and operational information over multiple quarters [Non-GAAP Financial Measures](index=8&type=section&id=Non-GAAP%20Financial%20Measures) Adjusted EBITDA is presented as a non-GAAP financial measure to provide insights into the company's operating performance, excluding the impact of capitalization structure and non-day-to-day operations. Management uses it for comparison, incentive compensation, planning, and evaluating operational strategies - Adjusted EBITDA is a non-GAAP measure used by management to compare operating performance, calculate incentive compensation, and for planning and strategy evaluation[22](index=22&type=chunk) - It excludes items such as depreciation, amortization, net interest expense, stock-based compensation, transaction costs, impairment of assets, and taxes from net income[22](index=22&type=chunk) - Adjusted EBITDA has limitations and should not be considered an alternative to GAAP measures like revenue or net income[22](index=22&type=chunk) [Reconciliation of Net Income to Adjusted EBITDA](index=8&type=section&id=Reconciliation%20of%20Net%20Income%20to%20Non-GAAP%20Adjusted%20EBITDA) The reconciliation table details the adjustments made to net income attributable to Viemed Healthcare, Inc. to arrive at Adjusted EBITDA for the past eight quarters, showing a Q1 2025 Adjusted EBITDA of $12.765 million Reconciliation of Net Income to Adjusted EBITDA | Metric (in thousands USD) | Q1 2025 | Q4 2024 | Q1 2024 | | :------------------------ | :------ | :------ | :------ | | Net Income attributable to Viemed Healthcare, Inc. | $2,625 | $4,316 | $1,603 | | Add back: | | | | | Depreciation & amortization | $6,613 | $6,366 | $6,285 | | Interest expense (income) | $179 | $147 | $150 | | Stock-based compensation | $2,311 | $1,521 | $1,432 | | Transaction costs | $85 | $11 | $110 | | Impairment of assets | — | — | — | | Income tax expense | $952 | $1,881 | $518 | | **Adjusted EBITDA** | **$12,765** | **$14,242** | **$10,098** | [Key Financial and Operational Information](index=9&type=section&id=Key%20Financial%20and%20Operational%20Information) This table provides a multi-quarter overview of key financial metrics such as revenue, gross profit, net income, cash, total assets, and Adjusted EBITDA, alongside operational metrics like ventilator, PAP therapy, and sleep resupply patient counts, illustrating trends over time Key Financial and Operational Information | Metric (in thousands USD, except patients) | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | | :--------------------------------------- | :------ | :------ | :------ | :------ | :------ | | Revenue | $59,129 | $60,695 | $58,004 | $54,965 | $50,593 | | Gross Profit | $33,279 | $36,138 | $34,371 | $32,892 | $29,802 | | Gross Profit % | 56% | 60% | 59% | 60% | 59% | | Net Income attributable to Viemed Healthcare, Inc. | $2,625 | $4,316 | $3,878 | $1,468 | $1,603 | | Cash and Cash Equivalents (As of) | $10,160 | $17,540 | $11,347 | $8,807 | $7,309 | | Total Assets (As of) | $178,079 | $177,069 | $169,526 | $163,947 | $154,875 | | Adjusted EBITDA | $12,765 | $14,242 | $13,954 | $12,813 | $10,098 | | Vent Patients | 11,809 | 11,795 | 11,374 | 10,905 | 10,450 | | PAP Therapy Patients | 22,899 | 21,338 | 19,478 | 17,349 | 15,726 | | Sleep Resupply Patients | 22,941 | 24,478 | 22,143 | 20,185 | 18,904 | [Legal Disclosures](index=4&type=section&id=Legal%20Disclosures) This section outlines the company's forward-looking statements and disclaimers regarding non-GAAP financial guidance [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) The press release contains forward-looking statements subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from expectations. The company does not undertake to publicly update these statements unless required by law - Forward-looking statements are identified by words such as 'plans,' 'expects,' 'intends,' and involve estimates, assumptions, and uncertainties that could cause actual results to differ materially[14](index=14&type=chunk) - Factors that could cause actual results to vary include general business conditions, reductions in reimbursement rates, competition, and difficulties integrating newly acquired businesses[14](index=14&type=chunk) - The company does not assume responsibility for the accuracy or completeness of such statements and undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law[14](index=14&type=chunk) [Non-GAAP Financial Guidance Disclaimer](index=4&type=section&id=Non-GAAP%20Financial%20Guidance%20Disclaimer) The company's non-GAAP financial guidance does not provide a GAAP reconciliation due to the unpredictability of certain items and explicitly excludes the impact of potential future strategic acquisitions - There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance due to the highly variable, difficult-to-project, and unusual nature of certain items[15](index=15&type=chunk) - The financial guidance excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified[16](index=16&type=chunk)

Core Insights - Viemed Healthcare, Inc. reported strong financial results for Q1 2025, with net revenues of $59.1 million, a 17% increase from Q1 2024, and net income of $2.6 million, a 64% increase year-over-year [6][5][19] - The company has updated its full-year 2025 guidance, raising the lower end of its revenue and Adjusted EBITDA ranges due to improved performance across its business segments [5][3] - Viemed announced an agreement to acquire Lehan's Medical Equipment for $26 million, which is expected to enhance its service offerings in respiratory care and women's health [4][6] Financial Performance - Net revenues for Q1 2025 were $59.1 million, up from $50.6 million in Q1 2024, reflecting an increase of $8.5 million [6][19] - Adjusted EBITDA for Q1 2025 was $12.8 million, representing a 26% increase compared to Q1 2024 [6][19] - The company reported a net income of $2.6 million, or $0.06 per diluted share, compared to $1.6 million, or $0.04 per diluted share in the same quarter last year [6][19] Operational Highlights - The number of ventilator patients increased to 11,809, a 13% rise from March 31, 2024 [6][24] - The PAP therapy patient count rose to 22,899, marking a 46% increase year-over-year [6][24] - The sleep resupply patient count was 22,941, a 21% increase from the previous year [6][24] Guidance and Future Outlook - For the full year 2025, net revenue is expected to be in the range of $256 million to $265 million, up from the previous range of $254 million to $265 million [6][3] - Adjusted EBITDA for the year is projected to be between $55 million and $58 million, an increase from the prior range of $54 million to $58 million [6][3] - The anticipated acquisition of Lehan's Medical Equipment is not included in the current guidance but is expected to contribute positively once completed [4][6] Balance Sheet and Cash Flow - As of March 31, 2025, the company had a cash balance of $10.2 million and total assets of $178.1 million [6][17] - Long-term debt stood at $3.5 million, with $55 million available under existing credit facilities [6][17] - The company reported a net cash provided by operating activities of $2.9 million for Q1 2025 [20]

Core Viewpoint - Viemed Healthcare, Inc. has announced a definitive agreement to acquire Lehan's Medical Equipment, enhancing its position in the home medical equipment market, particularly in respiratory care and women's health [1][2][3] Company Overview - Viemed Healthcare is a provider of in-home clinical care focused on post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators and sleep therapy [4] - Lehan's Medical Equipment, established in 1946, specializes in home medical equipment with a focus on women's health and respiratory care, operating three full-service locations in Northern Illinois and additional locations for sleep/CPAP setups [2][3] Financial Details - In 2024, Lehan generated net revenues of approximately $25.7 million and Adjusted EBITDA of approximately $7.4 million [3] - The acquisition is set to close in the third quarter of 2025 for a base purchase price of $26 million, with an estimated $2.2 million in contingent payments [3] Strategic Implications - The acquisition is expected to diversify Viemed's product mix into maternal health, leveraging existing payer relationships across the country [2] - Viemed's CEO highlighted the strong platform that Lehan provides for executing growth strategies in a large and fast-growing market [2]